Evidence map›Paper›PMID 28874539›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.

Joseph P Antonios, Horacio Soto, Richard G Everson, Diana L Moughon, Anthony C Wang, Joey Orpilla, Caius Radu, Benjamin M Ellingson, Jason T Lee, Timothy Cloughesy and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 94 citations in OpenAlex.

  1. Therapeutic targeting of the cGAS-STING pathway in human disease.The Journal of clinical investigation · 2026
    Review
  2. Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026
    Review
  3. Article
  4. Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Immune checkpoint inhibition: a future guided by radiology.The British journal of radiology · 2023
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. MRI techniques for immunotherapy monitoring.Journal for immunotherapy of cancer · 2022
    Review
  17. Review
  18. Article
  19. Visualizing T-Cell Responses: The T-Cell PET Imaging Toolbox.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Joseph P AntoniosDepartment of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Horacio SotoDepartment of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Richard G EversonDepartment of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Diana L MoughonDepartment of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Anthony C WangDepartment of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Joey OrpillaDepartment of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Caius RaduDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Benjamin M EllingsonJonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Jason T LeeDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Timothy CloughesyJonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Michael E PhelpsDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095; mphelps@mednet.ucla.edu rprins@mednet.ucla.edu.
Johannes CzerninDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095.
Robert M PrinsDepartment of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095; mphelps@mednet.ucla.edu rprins@mednet.ucla.edu.
University of California, Los Angeles · USUniversity of Colorado Cancer Center · USUniversity of Colorado Denver · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
PET Imaging-guided Personalized Therapy in Pancreatic CancerR01CA187678 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CZERNIN, JOHANNES, DONAHUE, TIMOTHY R · 2014 to 2018
$2.8M
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent GliomasR01CA125244 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIAU, LINDA M · 2010 to 2014
$2.4M
Optimizing Induction Conditions for Immunotherapeutic CTLR01CA154256 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PRINS, ROBERT M · 2010 to 2014
$1.9M
UCLA Neurosurgery Research Training and Education ProgramR25NS079198 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIAU, LINDA M · 2012 to 2021
$1.2M
Immunotherapeutic targeting of the Glioblastoma MutanomeR21CA186004 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARGAESPADA, DAVID ANDREW, PRINS, ROBERT M · 2015 to 2016
$380k
EPA EP-C-15-003NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA125244NCI NIH HHS R01 CA154256NCI NIH HHS R01 CA187678NCI NIH HHS R21 CA186004NINDS NIH HHS R25 NS079198
6 · The paper itself

Abstract

Contrast-enhanced MRI is typically used to follow treatment response and progression in patients with glioblastoma (GBM). However, differentiating tumor progression from pseudoprogression remains a clinical dilemma largely unmitigated by current advances in imaging techniques. Noninvasive imaging techniques capable of distinguishing these two conditions could play an important role in the clinical management of patients with GBM and other brain malignancies. We hypothesized that PET probes for deoxycytidine kinase (dCK) could be used to differentiate immune inflammatory responses from other sources of contrast-enhancement on MRI. Orthotopic malignant gliomas were established in syngeneic immunocompetent mice and then treated with dendritic cell (DC) vaccination and/or PD-1 mAb blockade. Mice were then imaged with [

Indexed as

AnimalsCell LineFemaleGlioblastomaHumansImmunotherapyMagnetic Resonance ImagingMiceMice, Inbred C57BLPositron-Emission Tomographycheckpoint blockadeglioblastomaimmunotherapyMRIPET

Identifiers

PMID28874539
PMCPMC5617282
OpenAlexW2753506647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.